Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer

Acta Oncol. 2018 Jan;57(1):156-159. doi: 10.1080/0284186X.2017.1407495. Epub 2017 Dec 5.

Authors

Lena H Rosvig¹, Sven T Langkjer¹, Ann Knoop², Anders B Jensen¹

Affiliations

¹ a Department of Oncology , Aarhus University Hospital , Aarhus , Denmark.
² b Department of Oncology , Odense University Hospital , Odense , Denmark.

PMID: 29202627
DOI: 10.1080/0284186X.2017.1407495

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Carboplatin / administration & dosage*
Carboplatin / adverse effects
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Disease Progression
Female
Gemcitabine
Humans
Middle Aged
Neoplasm Metastasis
Palliative Care*
Receptor, ErbB-2 / metabolism
Receptors, Estrogen / metabolism
Retreatment
Trastuzumab / administration & dosage
Treatment Outcome

Substances

Receptors, Estrogen
Deoxycytidine
Carboplatin
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab
Gemcitabine